Kymera's Sold Million Stock: Insider Move or Signal Ahead
Kymera’s CEO recently monetized a sizable stake after a strong run. This article unpacks the insider sale, what kymer...
Yearly Performance Of Total Market Index Funds
Yearly performance of total market index funds provides a broad view of winners and laggards. Use these insights to adjust your exposure today.
28,320 articles
Anchorage Releases First USAT Attestation for US Stablecoin
Anchorage Digital Bank released the first official USAT attestation, confirming $17.6 million in reserves backing Tet...
U.S. Metro Areas Where Builders Slashing New Home Prices
As existing-home prices hit record highs, builders in 10 U.S. metro areas are offering discounts on new homes. The mo...
Clarity Act Fallout: Trump Admin Tests Crypto Access
As the CLARITY Act stalls in the Senate, the Trump administration escalates pressure on banks to unlock crypto bankin...
This Investment Firm Says Crypto Could Bottom — Coinbase Signals
A respected investment firm hints that the crypto market might be near a bottom. Here’s what that could mean for Coin...
The Safest Dividend Kings Have Raised Dividends for 50 Years
In a turbulent market, five Dividend Kings have continuously raised payouts for more than half a century, underscorin...
Horton, Toll, Century Back AREC Fund Amid Tight AD&C Credit
Top U.S. homebuilders are backing Avila Real Estate Capital’s AREC Fund II, signaling a shift in housing finance as b...
Stocks Shaping Future Technology: 2 AI Bets to Buy Now
Two AI-driven stocks are at the forefront of the tech shift. This guide explains how they shape future technology, wh...
This Crispr Therapeutics Stock: Why It Fell Today So Far
Biotech investors woke up to a sharp move in this crispr therapeutics stock after CRISPR Therapeutics announced new d...
MasTec (MTZ) Up 150% Year, Analyst Sees More Upside
mastec (mtz) 150% year momentum drives the rally as the company backs a strong 2026 outlook. Analysts see upside as b...
Novartis (NVS) 2026 Earnings Outlook: Risks & Opportunities
Novartis faces a nuanced path in 2026, balancing new therapies with cost discipline. This guide breaks down the key d...
Nike Down From All-Time: Is This a Buy Opportunity Now?
Nike has fallen sharply from its peak, but a blue-chip brand can still offer compelling upside. This guide analyzes t...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status